Results 81 to 90 of about 4,675 (154)

Effect of Palmitoylethanolamide Compared to a Placebo on the Gut Microbiome and Biochemistry in an Overweight Adult Population: A Randomised, Placebo Controlled, Double-Blind Study

Biomedicines
This study investigates the effects of palmitoylethanolamide (PEA) on the gut microbiome of overweight adults. Fifty-eight participants (twenty males, thirty-eight females) aged 18–65 years with a BMI range of 30–40 kg/m2 were recruited.
Romeo Batacan, David Briskey, Yadav Sharma Bajagai, Chelsie Smith, Dana Stanley, Amanda Rao   +5 more
doaj   +1 more source

A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis

, 2019
Background: The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis.
Venkatesh, Ruchitha, Steels, Eleanor, Elizabeth Steels, Ruchitha Venkatesh, Eleanor Steels, Steels, Elizabeth, Vitetta, Gemma, Vitetta, Luis, Luis Vitetta, Gemma Vitetta   +9 more
core   +1 more source

Co-micronized palmitoylethanolamide/polydatin treatment causes endometriotic lesion regression in a rodent model of surgically-induced endometriosis

Frontiers in Pharmacology, 2016
Endometriosis is a chronic, painful disease characterized by the presence of endometrial glands and stroma outside the uterine cavity. Palmitoylethanolamide (PEA), an endogenous fatty acid amide, has anti-inflammatory and neuroprotective effects.
Rosanna Di Paola, Roberta Fusco, Enrico Gugliandolo, Rosalia Crupi, Maurizio Evangelista, Roberta Granese, Salvatore Cuzzocrea   +6 more
doaj   +1 more source

Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats

Frontiers in Pharmacology, 2018
Background: Liver fibrosis is a complex inflammatory and fibrogenic process, and the progression of fibrosis leads to cirrhosis. The only therapeutic approaches are the removal of injurious stimuli and liver transplantation. Therefore, the development of
Masatsugu Ohara, Shunsuke Ohnishi, Hidetaka Hosono, Koji Yamamoto, Qingjie Fu, Osamu Maehara, Goki Suda, Naoya Sakamoto   +7 more
doaj   +1 more source

Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders

, 2022
Increasing evidence strongly supports the key role of neuroinflammation in the pathophysiology of neurodegenerative diseases, such as Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis.
Di Lorenzo, Francesco, Di Lorenzo F., Martorana, Alessandro, Francesco Di Lorenzo, Martorana A., Koch, Giacomo, Martina Assogna, Assogna M., Alessandro Martorana, Giacomo Koch, Koch G., Assogna, Martina   +11 more
core   +1 more source

Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: a meta-analysis [PDF]

, 2017
Aim. To demonstrate clinical effectiveness of micronized palmitoylethanolamide-transpolydatin combination in reducing endometriotic chronic pelvic pain. Other endometriotic- pains were also assessed. Methods.
Indraccolo, Salvatore Renato, Indraccolo, Ugo, Mignini, Fiorenzo   +2 more
core   +1 more source

Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial

, 2019
OBJECTIVES: This preliminary randomized double-blind controlled trial was performed to test the efficacy of ultramicronized palmitoylethanolamide treatment in the burning mouth syndrome.
Rupel, Katia, Ottaviani, Giulia, Zoi, Valentina, Poropat, Augusto, Gobbo, Margherita, Biasotto, Matteo, Faraon, Michela, Di Lenarda, Roberto   +7 more
core   +1 more source

Palmitoylethanolamide (PEA): A New Drug For Intractable Pain

Palmitoylethanolamide (PEA) is a biochemical activated by the body for pain and inflammation control. Researchers have now determined dosages and several companies market PEA.
Ingrid Hollis, Forest Tennant DrPH, MPH, Md   +1 more
core   +1 more source

Galactosyl Prodrug of Palmitoylethanolamide: Synthesis, Stability, Cell Permeation and Cytoprotective Activity

, 2014
N-Palmitoylethanolamide (PEA) is emerging as a novel therapeutic agent in the treatment of neuropathic pain and neurodegenerative diseases. Unfortunately, PEA poorly reaches the central nervous system (CNS), after peripheral administration, since it is ...
Orefice N. S, Meli R, Avagliano C, Pinheiro Santiago G. M, Magliocca S, Nieddu M, Calignano A, Russo R, Luongo E, BOATTO, Gianpiero, A. Santoro A, Melisi D, Rimoli M. G., Mattace Raso G   +13 more
core   +2 more sources

Therapeutic potential of palmitoylethanolamide in neurodegenerative diseases

The therapeutic potential of palmitoylethanolamide (PEA) in the treatment of neurodegenerative diseases such as Alzheimer\u27s and Parkinson\u27s. He described how PEA, an endogenous compound with anti-inflammatory and neuroprotective properties, acted ...
Udovin , Lucas Daniel, Petrone Arifa, Isabela   +1 more
core   +1 more source